Everything is going great for the stock market right now. But a plot twist could be on the way.Think about a movie you've watched where everything seemed to be going great for the main character. What happened next? The character encountered a major problem that he or she had to get through, right? In Hollywood, the good times can't keep rolling for too long.It usually works that way in the stock market, too. Major market indexes are either at or near all-time highs. Investors applauded that the Federal Res ...

核心财务表现 - 预计季度每股收益0.64美元 同比下滑22% [1] - 预计季度营收138.8亿美元 同比下降6.7% [1] - 过去30天共识每股收益预期未出现修正 [1] 细分业务收入预期 - 肿瘤业务Ibrance全球收入预估8.99亿美元 同比下降14.7% [4] - 肿瘤业务Inlyta全球收入预估2.07亿美元 同比下降12.5% [5] - 肿瘤业务Ibrance美国收入预估5.66亿美元 同比下降16.7% [6] - 肿瘤业务Ibrance国际收入预估3.33亿美元 同比下降11.1% [7] - 肿瘤业务Inlyta美国收入预估1.16亿美元 同比下降17.8% [8] - 肿瘤业务Inlyta国际收入预估9142万美元 同比下降4.8% [8] 专科护理业务表现 - 专科护理Cibinqo收入预估7120万美元 同比增长69.5% [4] - 专科护理Xeljanz全球收入预估1.42亿美元 同比下降26.9% [5] - 专科护理Xeljanz美国收入预估4010万美元 同比下降45.8% [7] - 专科护理Xeljanz国际收入预估1.02亿美元 同比下降15.2% [6] 初级保健业务数据 - 初级保健Prevnar美国收入预估11.4亿美元 同比下降0.4% [9] - 初级保健Prevnar国际收入预估5.5亿美元 同比增长1.6% [9] 股价表现与市场对比 - 过去一个月股价回报率-11.2% 同期标普500指数回报率-5.1% [9] - 当前Zacks评级为2级(买入) 预示可能跑赢整体市场 [10]